Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Net Income towards Common Stockholders: 2020-2023

Historic Net Income towards Common Stockholders for Candel Therapeutics (CADL) over the last 4 years, with Dec 2023 value amounting to -$5.4 million.

  • Candel Therapeutics' Net Income towards Common Stockholders rose 31.61% to -$5.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$33.7 million, marking a year-over-year increase of 3.54%. This contributed to the annual value of -$30.2 million for FY2024, which is 10.44% up from last year.
  • According to the latest figures from Q4 2023, Candel Therapeutics' Net Income towards Common Stockholders is -$5.4 million, which was up 40.34% from -$9.0 million recorded in Q3 2023.
  • In the past 5 years, Candel Therapeutics' Net Income towards Common Stockholders registered a high of -$2.4 million during Q2 2020, and its lowest value of -$9.8 million during Q2 2023.
  • Over the past 3 years, Candel Therapeutics' median Net Income towards Common Stockholders value was -$8.5 million (recorded in 2021), while the average stood at -$7.9 million.
  • Per our database at Business Quant, Candel Therapeutics' Net Income towards Common Stockholders tumbled by 197.01% in 2021 and then surged by 31.61% in 2023.
  • Over the past 4 years, Candel Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$6.1 million in 2020, then declined by 27.57% to -$7.8 million in 2021, then declined by 1.60% to -$7.9 million in 2022, then soared by 31.61% to -$5.4 million in 2023.
  • Its Net Income towards Common Stockholders was -$5.4 million in Q4 2023, compared to -$9.0 million in Q3 2023 and -$9.8 million in Q2 2023.